Sanity Group
Press Page


For all kind of media inquiries

Thilo Grösch

Public Relations | Press Officer

Email: |

Phone: +49 30 80093764

Address: Sanity Group GmbH
Jägerstraße 28-31 | 10117 Berlin | Germany

For other inquiries please contact:

About the Sanity Group

Unlocking the health benefits of cannabinoids


Founded in


is our headquarters, near Frankfurt a. M. is the location of our extraction facility


Employees from over 15 different nations

Sanity Group, a Berlin based health and life-science company, aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on pharmaceuticals and medical products (Sanity Medical) on the one hand and cannabinoid-based consumer goods (Sanity Care) on the other. The mission is to build the leading cannabinoid company for medical cannabis and consumer health in Europe. Financially and strategically, Sanity Group is supported by investors such as Redalpine, HV Capital, Calyx, Casa Verde Capital, Navy Capital, SOJE Capital, Bitburger Ventures, and various business angels such as music producer, Hollywood actor Alyssa Milano, professional soccer player Mario Götze and German model Stefanie Giesinger.

Our three business areas:


Sanity Medical: The medical business unit of the Sanity Group, with our subsidiaries Vayamed, Belfry Medical and Endosane Pharmaceuticals.

Consumer Health

Sanity Care: The consumer health division of the Sanity Group with the brands VAAY (wellbeing), This Place (functional natural cosmetics) and Sanatio CBD (classic CBD).

Production & Research

Sanity Science: The Research & Development division of the Sanity Group with a production facility for cannabis extracts near Frankfurt a. M., Germany.

Our brands & subsidiaries

Sanity Care:

VAAY is the brand for CBD and hemp-based lifestyle products to promote mindfulness, balance and well-being as part of a healthy lifestyle, and is one of Germany’s best-known CBD lifestyle brands.

This Place is a new kind of natural cosmetics: in each product CBD and different, purely natural ingredients are combined in such a way that they can show their full power together.

Sanatio CBD is Sanity Group’s third and newest consumer health brand – a classic CBD brand with a core focus on CBD purists aged +45. At the moment in the test phase after softlaunch.

Sanity Medical:

Vayamed, a pharmaceutical company, develops innovative cannabinoid-based medicines for the European market and distributes them to pharmacies and clinical institutions.

Belfry Medical focuses on the development and application of innovative technologies for the medical cannabis market, including unique medical devices as well as digital health applications.

Endosane Pharmaceuticals develops pharmaceuticals for the treatment of neuropsychiatric and psychiatric disorders such as schizophrenia or anxiety disorders.

Press pictures

Download portraits of our founders in high-res and web optimized resolution

Go to selection

Sanity Group Logo

Download the Sanity Group logo in various formats

Go to selection

Info & Factsheet (PDF)

English version coming soon!

Download (German)

Short bio Founders (PDF)

Short biographies of the Sanity Group Founders



“Unfortunately, Cannabis still has very often a negative stigma attached to it. We want to give the plant a new chance, because what people associate with it is based on old prejudices. It’s important to us to actively contribute to education and knowledge transfer. This also involves showing decision-makers the differences between cannabis as a medicine, agricultural substance and lifestyle product. It’s important to understand the full potential of the plant – that’s what we’re working for, to bring cannabis back to the center of society.”

Finn A. Hänsel, Founder & Managing Director


“Everyone should be able to live a healthy life. When you hear the stories of people who have suffered from the side effects of a particular medication for a long time, and their quality of life has improved because of cannabis, that’s reason enough to keep researching it. At present, many doctors, pharmacists and patients are often unaware of the medical benefits that cannabis has to offer. This is where we want to raise awareness – and we will also invest in research to do so.”

Fabian Friede, Founder & Managing Director

Fabian Friede, Founder & Managing Director Sanity Group | Fotocredit: Sanity Group

Latest News

Sanity Group Closes $3.5M Follow-On Investment by Casa Verde Capital

Berlin-based cannabis start-up Sanity Group announced today it has closed a $3.5M follow-on investment from Casa Verde Capital, representing a second closing of the company’s $45M Series A financing round. This brings total funds raised by Sanity Group to $76.5M to date. The Venture firm’s first investment into Germany further cements Casa Verde’s European foothold.

Read more

Endosane: International scientists team up with Sanity Group in a joint-venture aiming to develop a new generation of “game changing” psychiatric drugs with significantly reduced side effect profile​

Berlin, October 5th, 2021 – Sanity Group, a health and life-science company focused on natural compounds and cannabinoids, and an international team of scientists are now jointly developing pharmaceuticals for the treatment of neuropsychiatric and psychiatric disorders such as schizophrenia or anxiety disorders. This collaboration is based on the systematic

Read more

Liqui-Patch: Sanity Group and epinamics launch strategic partnership for transdermal cannabinoid applications

Berlin, September 22, 2021 – Berlin-based health and life science company Sanity Group and Berlin-based tech company epinamics are launching a strategic innovation partnership: Sanity Group will receive exclusive usage and marketing rights for epinamics’ patented Liqui-Patch® technology for all cannabinoid market segments and markets in the EU, UK and

Read more

Subscribe to press releases

We are happy to provide journalists, bloggers and media representatives with relevant information about Sanity Group on a regular basis. Subscribe to our press distribution list to receive our press releases directly in the future.

We would also be pleased if you keep us informed about publications and send us a specimen copy (gladly as a PDF) to Thank you very much!